AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

CARCLO PLC

Board/Management Information Apr 1, 2015

5252_rns_2015-04-01_e9a31082-ad92-4890-bfc7-1ac20f2226d6.html

Board/Management Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0819J

Carclo plc

01 April 2015

31 March 2015

Carclo plc ("Carclo")

Board change

The board announces that David Toohey has been appointed to the Carclo plc board as a non-executive director with effect from 1 April 2015.

David Toohey has over 30 years' experience in international business, the last 20 of which have been in medical devices and the In Vitro Diagnostics ('IVD') industry. He has been Chief Executive Officer of Syncrophi Systems Limited ("Syncrophi"), since 2012. He joined Syncrophi from Alere Inc, the global diagnostics and health management company, where he spent 11 years in senior managerial roles, latterly as President of International Business Operations. Mr. Toohey held various Executive positions at Boston Scientific Corporation, Bausch & Lomb, Inc., Digital Equipment Corp. and Mars, Inc. He has been an Independent Non-Executive Director at EKF Diagnostics Holdings plc since August 2014.

There are no further disclosures relating to David Toohey required under paragraph 9.6.13R of the Listing Rules.

Enquiries:
Carclo plc 01924 268040
Chris Malley, Chief Executive
Robert Brooksbank, Finance Director
Peel Hunt LLP 0207 418 8900
Justin Jones
Jock Maxwell Macdonald
Mike Bell
N+1 Singer 0207 496 3000
Shaun Dobson
Richard Lindley
Weber Shandwick Financial 020 7067 0700
Nick Oborne
Tom Jenkins

Notes to editors

Carclo plc is a public company whose shares are quoted on the London Stock Exchange.

Carclo's strategy is to develop and expand its key manufacturing assets where there remain significant further opportunities to drive value. To enhance profit margins the group has been investing in new technologies.

Approximately three fifths of revenues are currently derived from the supply of fine tolerance, injection moulded plastic components, mainly for medical products. The balance of revenue is derived mainly from the design and supply of specialised injection moulded LED based lighting systems to the low volume premium automotive industry.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAWGUMAWUPAGQG

Talk to a Data Expert

Have a question? We'll get back to you promptly.